<DOC>
	<DOCNO>NCT01587066</DOCNO>
	<brief_summary>Quetiapine one atypical antipsychotic good efficacy well side effect profile conventional antipsychotic , widely use beyond treatment schizophrenia . Recently , BOLDER I II study show quetiapine monotherapy effective well-tolerated treatment depressive episode bipolar disorder . However , c1inicians confidence quetiapine monotherapy yet , practice guideline recommend monotherapy mood stabilizer first-line treatment . The Korean medication algorithm bipolar disorder publish 2006 also recommend monotherapy lithium , divalproex , lamotrigine treatment mild moderate depressive episode bipolar disorder . Therefore , aim study investigate efficacy safety quetiapine monotherapy compare mood stabilizer monotherapy . In addition , investigator go reveal quality sleep quality life , two group patient .</brief_summary>
	<brief_title>Efficacy Quetiapine XR Versus Divalproex Clinical Outcome Quality Sleep Quality Life Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Provision write informed consent A diagnosis Bipolar depression Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) Females male age 20 65 year Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study HAMD score Visit 0 Visit 1 20 . Willingness adhere schedule assessment Able willing comply selfadministration study drug , consistent help support available Pregnancy lactation Any DSMIV Axis 1 disorder define inclusion criterion Patients , opinion investigator , pose imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate divalproex , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrollment include limited : ketoconazole , itraconazole , fluconazole , erγthromycin， clarithromycin , troleandomycin , indinavir , nelfinavir，ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 3A4 inducer 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin， St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomisation Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) ， define DSMIV criterion Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 8 week prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e , g , congestive heart failure , angina pectoris , hypertension ) judge investigator Invo1vement planning conduct study Previous enrollment randomisation treatment present study . Participation another drug trial within 8 week prior enrollment study long accordance local requirement A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrolment glycosylated hemoglobin ( HbAlc ) &gt; 8.5 % Admitted hospital treatment DM DM relate illness past 12 week Not physician care DM Physician responsib1e patient 's DM care indicate patient 's DM control Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 Weeks Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study An absolute neutrophil count ( ANC ) 1.5 x 109 per liter</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>